CPIX
HEALTHCARECumberland Pharmaceuticals Inc
$4.37-0.18 (-3.96%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CPIX Today?
No stock-specific AI insight has been generated for CPIX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.85$6.26
$4.37
Fundamentals
Market Cap$65M
P/E Ratio—
EPS$-0.49
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume194K
Avg Volume (10D)—
Shares Outstanding15.0M
CPIX News
20 articles- Cumberland Posts Loss in Q1 Amid $100M Apotex Deal PlanYahoo Finance·May 6, 2026
- Cumberland Pharmaceuticals Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Cumberland Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATEYahoo Finance·May 5, 2026
- Cumberland Pharmaceuticals (CPIX) Integrates Commercial Business with ApotexYahoo Finance·May 5, 2026
- CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATEYahoo Finance·Apr 28, 2026
- Broadwind And 2 Promising Penny Stocks For Your Investment RadarYahoo Finance·Apr 24, 2026
- Cumberland to sell drug portfolio to Apotex for $100mHospitalmanagement·Apr 24, 2026
- Cumberland Pharmaceuticals jumps on $100M Apotex transactionAdvfn·Apr 23, 2026
- Apotex Announces Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded BusinessesYahoo Finance·Apr 23, 2026
- Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with ApotexYahoo Finance·Apr 23, 2026
- RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026Yahoo Finance·Apr 22, 2026
- CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITEYahoo Finance·Apr 16, 2026
- Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and VomitingYahoo Finance·Mar 17, 2026
- Cumberland Q4 Loss Narrows Y/Y as Talicia Launch Boosts SalesYahoo Finance·Mar 10, 2026
- Cumberland Pharmaceuticals Inc (CPIX) Q4 2025 Earnings Call Highlights: Revenue Surge and ...Yahoo Finance·Mar 4, 2026
- Cumberland Pharmaceuticals Q4 Earnings Call HighlightsMarketbeat·Mar 3, 2026
- Cumberland: Q4 Earnings SnapshotYahoo Finance·Mar 3, 2026
- CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTHYahoo Finance·Mar 3, 2026
- CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®Yahoo Finance·Feb 25, 2026
All 20 articles loaded
Price Data
Open$4.51
Previous Close$4.55
Day High$4.72
Day Low$4.35
52 Week High$6.26
52 Week Low$1.85
52-Week Range
$1.85$6.26
$4.37
Fundamentals
Market Cap$65M
P/E Ratio—
EPS$-0.49
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume194K
Avg Volume (10D)—
Shares Outstanding15.0M
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and marketing of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company is headquartered in Nashville, Tennessee.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—